Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04715646 · ClinicalTrials.gov registry record · Phase 3
A Study to Test the Safety and Tolerability of Brivaracetam in Children and Adolescents With Seizures
A Phase 3 study of Epilepsy, sponsored by UCB Biopharma SRL.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 70
- Enrollment target
- 20
- Study locations
NCT04715646 is a Phase 3 study of Epilepsy that is actively recruiting participants, run by UCB Biopharma SRL. The registered enrollment target is 70 participants, below the 952-participant average among 160 other Epilepsy trials with a reported enrollment target (93% lower). The trial reports 20 study locations across 3 states.
The verdict
NCT04715646, a Phase 3 study of Epilepsy, is actively recruiting participants, sponsored by UCB Biopharma SRL.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 70 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the study is to evaluate the long-term safety and tolerability of brivaracetam.
Conditions Studied
Interventions
- DRUG Brivaracetam
Study Locations (20)
Other
- Ep0156 204 - Leuven
- Ep0156 240 - Prague
- Ep0156 207 - Loos
- Ep0156 209 - Freiburg im Breisgau
- Ep0156 210 - Budapest
- Ep0156 247 - Budapest
- Ep0156 232 - Miskolc
- Ep0156 230 - Roma
- Ep0156 803 - Bunkyō City
- Ep0156 808 - Chūō
- Ep0156 800 - Gifu
- Ep0156 807 - Hiroshima
- Ep0156 815 - Kodaira-shi
- Ep0156 813 - Kōshi
- Ep0156 806 - Kyoto
- Ep0156 811 - Nagoya
- Ep0156 812 - Niigata
- Ep0156 817 - Osaka
New York
- Ep0156 259 - Hawthorne
North Carolina
- Ep0156 237 - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2021-03-11 |
| Est. Completion | 2030-07-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04715646
The ClinicalTrials.gov registry entry for NCT04715646 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 952-participant average among 160 other Epilepsy trials with a reported enrollment target (93% lower). The listed sponsor is UCB Biopharma SRL, which has 82 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Epilepsy appearing as the primary indexed condition, and to 1 intervention - of which Brivaracetam is the first listed.
NCT04715646 reports 20 study locations spanning 3 distinct geographic areas - top geographies include Other, New York, North Carolina.
Frequently Asked Questions
What is clinical trial NCT04715646 about?
NCT04715646 is a clinical study titled "A Study to Test the Safety and Tolerability of Brivaracetam in Children and Adolescents With Seizures". The purpose of the study is to evaluate the long-term safety and tolerability of brivaracetam.
What is the current status of trial NCT04715646?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 70 participants. The study started on 2021-03-11. Estimated completion is 2030-07-08.
What conditions does trial NCT04715646 study?
This clinical trial studies the following conditions: Epilepsy.
What interventions are being tested in trial NCT04715646?
The interventions under investigation include: Brivaracetam (DRUG).
Who is sponsoring clinical trial NCT04715646?
This trial is sponsored by UCB Biopharma SRL, which has 82 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04715646 being conducted?
This trial has 20 study locations across New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Epilepsy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Lemborexant Treatment of Insomnia Linked to Epilepsy
RECRUITING · Phase 3
-
RNS System NAUTILUS Study
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults
COMPLETED · Phase 3
-
Clobazam in Patients With Lennox-Gastaut Syndrome
COMPLETED · Phase 3
-
Pediatric Epilepsy Study
COMPLETED · Phase 3
-
IV Lacosamide: The Safety of Intravenous Lacosamide
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.